Drugmaker AstraZeneca See Profits Jump

Oct. 29, 2009
H1N1 vaccine sales contributed

Anglo-Swedish pharmaceuticals giant AstraZeneca said on Oct.29 its third-quarter net profit rose 22.3% from the level 12 months ago to $2.115 billion dollars.

AstraZeneca added that sales rose 5.5% to reach $8.2 billion in the three months to the end of September, compared with the same part of 2008.

"Our strong business performance is driven by good operating execution bolstered by revenue upsides from Toprol-XL and H1N1 vaccine sales," said Chief Executive David Brennan.

The company was boosted by strong sales of hypertension treatment Toprol XL and also the cholesterol drug Crestor.

Copyright Agence France-Presse, 2009

Popular Sponsored Recommendations

Empowering the Modern Workforce: The Power of Connected Worker Technologies

March 1, 2024
Explore real-world strategies to boost worker safety, collaboration, training, and productivity in manufacturing. Emphasizing Industry 4.0, we'll discuss digitalization and automation...

3 Best Practices to Create a Product-Centric Competitive Advantage with PRO.FILE PLM

Jan. 25, 2024
Gain insight on best practices and strategies you need to accelerate engineering change management and reduce time to market. Register now for your opportunity to accelerate your...

How Manufacturers Can Optimize Operations with Weather Intelligence

Nov. 2, 2023
The bad news? Severe weather has emerged as one of the biggest threats to continuity and safety in manufacturing. The good news? The intelligence solutions that build weather ...

Transformative Capabilities for XaaS Models in Manufacturing

Feb. 14, 2024
The manufacturing sector is undergoing a pivotal shift toward "servitization," or enhancing product offerings with services and embracing a subscription model. This transition...

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!